Clinical usefulness of plasma androstanediol glucuronide measurements in women with idiopathic hirsutism.
Serum androstanediol glucuronide (3 alpha-diol G), a metabolite of the active androgens dihydrotestosterone and androstanediol, was elevated in 28 consecutive women with idiopathic hirsutism (IH). The mean 3 alpha-diol G level in the women with IH was 487 +/- 192 (+/- SD) ng/dL compared to 119 +/- 37 ng/dL in normal women (n = 50), and only 1 patient had a value overlapping with the normal range. Since 3 alpha-diol G appears to be formed entirely in target organs and has a long serum half-life, we studied its clinical usefulness by following women with IH during treatment. In 15 of 17 women with IH treated for 1-4 yr with glucocorticoids, contraceptives, or spironolactone, serum 3 alpha-diol G levels changed concordantly with clinical responses, in contrast to the poor concordance of serum testosterone (5 of 17), free testosterone (7 of 17), and androstenedione (7 of 17). Specifically, in IH patients treated with spironolactone, serum testosterone, free testosterone, and androstenedione levels changed little, yet clinical improvement frequently occurred, and this improvement was reflected by concomitantly lowered 3 alpha-diol G levels. Further, in 4 IH patients, discontinuation of effective therapy resulted in prompt increases in serum 3 alpha-diol G as harbingers of worsening hair growth. We, thus, conclude that serum 3 alpha-diol G measurements are clinically useful in evaluating hirsute women and correlate with the clinical responses to therapy.
Kirschner
M A
MA
Newark Beth Israel Medical Center, University of Medicine and Dentistry of New Jersey 07112.
Samojlik
E
E
Szmal
E
E
D000293:Adolescent; D000328:Adult; D015113:Androstane-3,17-diol / Q000031:analogs & derivatives / Q000097:blood*; D000732:Androstanols / Q000097:blood*; D003277:Contraceptives, Oral, Combined / Q000627:therapeutic use; D003280:Contraceptives, Oral, Synthetic / Q000627:therapeutic use; D004338:Drug Combinations; D005260:Female; D006628:Hirsutism / Q000097:blood* / Q000188:drug therapy; D006801:Humans; D008656:Mestranol / Q000627:therapeutic use; D008991:Monitoring, Physiologic; D009640:Norethindrone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D013997:Time Factors
D000732:Androstanols; D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D004338:Drug Combinations; D015113:Androstane-3,17-diol; C028895:androstane-3,17-diol glucuronide; D013148:Spironolactone; C014715:Norinyl; D008656:Mestranol; D009640:Norethindrone; D011241:Prednisone